Antibody Drug Conjugates in Mexico: Key Players, Innovations, and Market Insights
The Mexico antibody-drug conjugates (ADC) market is growing due to increasing cancer prevalence, advancements in targeted therapies, and rising healthcare investments. ADCs offer precise drug delivery with reduced side effects, driving their adoption in oncology treatments. Government initiatives, expanding clinical research, and collaborations between pharmaceutical companies further support market growth. The demand for innovative biologics and personalized medicine is expected to propel the market in the coming years.